Author:
Aldossary Khlood Mohammad,Ali Lashin Saad,Abdallah Mahmoud S.,Bahaa Mostafa M.,Elmasry Thanaa A.,Elberri Eman I.,Kotkata Fedaa A.,El Sabaa Ramy M.,Elmorsi Yasmine M.,Kamel Mostafa M.,Negm Walaa A.,Elberri Aya Ibrahim,Hamouda Amir O.,AlRasheed Hayam Ali,Salahuddin Muhammed M.,Yasser Mohamed,Hamouda Manal A.
Abstract
BackgroundNeuroinflammation pathways have been associated with the development of major depressive disorders (MDD). The anti-inflammatory characteristics of statins have been demonstrated to have significance in the pathophysiology of depression.AimTo investigate the mechanistic pathways of high dose atorvastatin in MDD.Patients and methodsThis trial included 60 patients with MDD who met the eligibility requirements. Two groups of patients (n = 30) were recruited by selecting patients from the Psychiatry Department. Group 1 received 20 mg of fluoxetine plus a placebo once daily. Group 2 received fluoxetine and atorvastatin (80 mg) once daily. All patients were assessed by a psychiatrist using the Hamilton Depression Rating Scale (HDRS). A HDRS score of ≤7 indicates remission or partial remission [HDRS<17 and>7]. Response was defined as ≥ 50% drop in the HDRS score. The serum concentrations of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP-3), interleukin-6 (IL-6), adenosine monophosphate activated protein kinase (AMPK), and signal transducer and activator of transcription factor-3 (STAT-3) were measured.ResultsThe atorvastatin group showed a significant reduction in the levels of all measured markers along with a statistical increase in the levels of AMPK when compared to the fluoxetine group. The atorvastatin group displayed a significant decrease in HDRS when compared to its baseline and the fluoxetine group. The response rate and partial remission were higher in the atorvastatin group than fluoxetine (p = 0.03, and p = 0.005), respectively.ConclusionThese results imply that atorvastatin at high doses may be a promising adjuvant therapy for MDD patients by altering the signaling pathways for AMPK/NLRP3 and IL-6/STAT-3.Clinical Trial Registrationclinicaltrials.gov, identifier NCT05792540.